Jiang Yu, Liu Gang, Deng Bowen, Bai Huizhong, Mu Xiaohong
Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
J Orthop Surg Res. 2025 Aug 8;20(1):748. doi: 10.1186/s13018-025-06129-9.
Chinese herbal medicine (CHM) is widely used for the treatment of spinal cord injury (SCI). However, its exact mechanisms are not yet fully understood.
The aim of this study was to evaluate the clinical efficacy and potential pharmacological mechanisms of CHM in treating SCI.
Eight databases were searched for randomized controlled trials (RCTs) published from their inception until January 2025 regarding the use of Chinese medicine for SCI. The quality of the included studies was assessed using the Cochrane risk of bias tool. A meta-analysis was performed to evaluate the efficacy of Chinese medicine in treating SCI, and data mining and network pharmacology were used to identify core drugs and active ingredients. Finally, clustering and enrichment analyses were performed to explore potential targets and signaling pathways.
A total of 41 studies involving 2,483 patients were included. The meta-analysis showed that compared with the control group, the Chinese medicine group significantly improved sensory function (ASIS-SIS), motor function (ASIS-MS), activities of daily living (BI), and pain levels (VAS) in patients with SCI: ASIS-SIS: standardized mean difference (SMD) = 11.52, 95% confidence interval (CI) (10.52, 12.51), p = 0.02 < 0.05, heterogeneity (I) = 45%;ASIS-MS: SMD = 7.46, 95% CI (6.03, 8.9), p < 0.00001, I = 66% BI: SMD = 6.73, 95% CI (5.60, 7.89), p = 0.0001, I = 62%;VAS: SMD = -1.05, 95% CI (-1.43, -0.67), p < 0.00001, I = 89%.From the 41 Chinese medicine prescriptions for SCI treatment, 9 core herbs were selected based on their frequent use and strong correlation. A total of 440 drugs intersecting with disease targets were identified. A "drug-component-intersecting target network" was constructed, revealing the top ten core active ingredients. The core target protein-protein interaction (PPI) network identified 92 core targets. Based on these, clustering and enrichment analyses were performed to explore the related pharmacological mechanisms, primarily including anti-inflammatory, anti-apoptotic, and oxidative stress regulation.
Compared to conventional treatments, Chinese medicine is effective in alleviating the symptoms of SCI. However, due to the difficulty of implementing blinded oral administration of Chinese medicine formulas, more high-quality studies are needed in the future. Chinese medicine formulas have the advantage of multi-component and multi-target action in treating SCI, and their active ingredients can improve the pathological environment of SCI through various mechanisms.
Not applicable.
CRD42025641947.
中药广泛应用于脊髓损伤(SCI)的治疗。然而,其确切机制尚未完全明确。
本研究旨在评估中药治疗SCI的临床疗效及潜在药理机制。
检索8个数据库,查找自数据库建库至2025年1月发表的关于中药治疗SCI的随机对照试验(RCT)。使用Cochrane偏倚风险工具评估纳入研究的质量。进行荟萃分析以评估中药治疗SCI的疗效,并运用数据挖掘和网络药理学方法识别核心药物及活性成分。最后,进行聚类和富集分析以探索潜在靶点和信号通路。
共纳入41项研究,涉及2483例患者。荟萃分析显示,与对照组相比,中药组显著改善了SCI患者的感觉功能(ASIS - SIS)、运动功能(ASIS - MS)、日常生活活动能力(BI)和疼痛程度(VAS):ASIS - SIS:标准化均数差(SMD)= 11.52,95%置信区间(CI)(10.52,12.51),p = 0.02 < 0.05,异质性(I)= 45%;ASIS - MS:SMD = 7.46,95% CI(6.03,8.9),p < 0.00001,I = 66%;BI:SMD = 6.73,95% CI(5.60,7.89),p = 0.0001,I = 62%;VAS:SMD = -1.05,95% CI(-1.43,-0.67),p < 0.00001,I = 89%。从41个治疗SCI的中药方剂中,基于其频繁使用和强相关性筛选出9味核心药材。共识别出与疾病靶点相交的440种药物。构建了“药物 - 成分 - 相交靶点网络”,揭示了十大核心活性成分。核心靶点蛋白质 - 蛋白质相互作用(PPI)网络识别出92个核心靶点。基于此,进行聚类和富集分析以探索相关药理机制,主要包括抗炎、抗凋亡和氧化应激调节。
与传统治疗相比,中药在缓解SCI症状方面有效。然而,由于中药方剂实施盲法口服困难,未来需要更多高质量研究。中药方剂在治疗SCI方面具有多成分、多靶点作用的优势,其活性成分可通过多种机制改善SCI的病理环境。
不适用。
PROSPERO注册号:CRD42025641947。